nach oben

European Journal of Nutrition

Erschienen in:

23.02.2021 | Original Contribution

RETRACTED ARTICLE: A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis

Erschienen in: European Journal of Nutrition | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Coenzyme Q10 (CoQ10), having potent antioxidant and anti-inflammatory pharmacological properties, has recently been shown to be a safe and promising agent in maintaining remission of ulcerative colitis (UC). This trial was, therefore, designed to determine CoQ10 efficacy on inflammation and antioxidant status, antimicrobial peptides, and microRNA-146a expression in UC patients.

Methods

In this randomized double-blind controlled trial, 88 mild-to-moderate UC patients were randomly allocated to receive CoQ10 (200 mg/day) or placebo (rice flour) for 2 months. At the baseline and at an 8-week follow-up, serum levels of Nrf2, cathelicidin LL-37, β-defensin 2, IL-10, IL-17, NF-κB p65 activity in peripheral blood mononuclear cells (PBMCs), simple clinical colitis activity index questionnaire (SCCAIQ), and quality of life (IBDQ-32 score), as well as an expression rate of microRNA-146a were measured.

Results

A significant reduction was detected in the serum IL-17 level, activity of NF-κB p65 in PBMCs, and also SCCAI score in the CoQ10 group compared to the placebo group, whereas IL-10 serum concentrations and IBDQ-32 score of the CoQ10 group considerably increased versus the control group; the changes of these variables were also significantly different within and between groups at the end of the study. Furthermore, CoQ10 remarkably increased serum levels of cathelicidin LL-37. A significant change in serum cathelicidin LL-37 levels was also observed between the two groups. No statistical difference, however, was seen between the two groups in terms of the serum levels of Nrf2 and β-defensin 2 and the relative expression of microRNA-146a.

Conclusions

Our results indicate that CoQ10 supplementation, along with drug therapy, appears to be an efficient reducer of inflammation in patients with mild-to-moderate UC at a remission phase.

Trial Registration

The research has also been registered at the Iranian Registry of Clinical Trials (IRCT): IRCT20090822002365N17.

Graphic abstract

Nur mit Berechtigung zugänglich

Bai X, Gou X, Cai P, Xu C, Cao L, Zhao Z, Huang M, Jin J (2019) Sesamin enhances Nrf2-mediated protective defense against oxidative stress and inflammation in colitis via AKT and ERK activation. Oxid Med Cell Longev 2019:2432416. https://doi.org/10.1155/2019/2432416CrossRefPubMedPubMedCentral

Yang L, Song Y, Jin P, Liu Y, Wang Y, Qiao H, Huang Y (2018) Shen–Ling–Bai–Zhu–San for ulcerative colitis: protocol for a systematic review and meta-analysis. Medicine 97(38):e12337. https://doi.org/10.1097/MD.0000000000012337CrossRefPubMedPubMedCentral

Okabayashi S, Kobayashi T, Hibi T (2020) Inflammatory bowel disease in Japan-is it similar to or different from Westerns? J Anus Rectum Colon 4(1):1–13. https://doi.org/10.23922/jarc.2019-003CrossRefPubMedPubMedCentral

Ficagna GB, Dalri JL, Malluta EF, Scolaro BL, Bobato ST (2020) Quality of life of patients from a multidisciplinary clinic of inflammatory bowel disease. Arq Gastroenterol 57(1):8–12. https://doi.org/10.1590/s0004-2803.202000000-03CrossRefPubMed

Malekzadeh MM, Vahedi H, Gohari K, Mehdipour P, Sepanlou SG, Ebrahimi Daryani N, Zali MR, Mansour-Ghanaei F, Safaripour A, Aghazadeh R (2016) Emerging epidemic of inflammatory bowel disease in a middle income country: a nation-wide study from Iran. Arch Iran Med 19(1):2–15PubMed

Neubauer K, Kempinski R, Matusiewicz M, Bednarz-Misa I, Krzystek-Korpacka M (2019) Nonenzymatic serum antioxidant capacity in IBD and its association with the severity of bowel inflammation and corticosteroids treatment. Medicina 55(4):88. https://doi.org/10.3390/medicina55040088CrossRefPubMedCentral

Chen YX, Zhang XQ, Yu CG, Huang SL, Xie Y, Dou XT, Liu WJ, Zou XP (2019) Artesunate exerts protective effects against ulcerative colitis via suppressing toll-like receptor 4 and its downstream nuclear factor-κB signaling pathways. Mol Med Rep 20(2):1321–1332. https://doi.org/10.3892/mmr.2019.10345CrossRefPubMedPubMedCentral

Kim K-J, Park J-M, Lee J-S, Kim Y, Kangwan N, Han Y-M, Kang E, An J, Park Y, Hahm K-B (2018) Oligonol prevented the relapse of dextran sulfate sodium-ulcerative colitis through enhancing NRF2-mediated antioxidative defense mechanism. J Physiol Pharmacol. https://doi.org/10.26402/jpp.2018.3.0CrossRefPubMed

Sands BE (2015) Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology 149(5):1275–1285. https://doi.org/10.1053/j.gastro.2015.07.003CrossRefPubMed

10.

Guo C, Wu K, Liang X, Liang Y, Li R (2019) Infliximab clinically treating ulcerative colitis: a systematic review and meta-analysis. Pharmacol Res 148:104455. https://doi.org/10.1016/j.phrs.2019.104455CrossRefPubMed

11.

Motaghi E, Ghasemi-Pirbaluti M, Zabihi M (2019) Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: a systematic review and indirect comparison. Pharmacol Res 139:120–125. https://doi.org/10.1016/j.phrs.2018.11.003CrossRefPubMed

12.

Lee S-Y, Lee SH, Yang E-J, Kim J-K, Kim E-K, Jung K, Jung H, Lee K, Lee HH, Lee B-I (2017) Coenzyme Q10 inhibits Th17 and STAT3 signaling pathways to ameliorate colitis in mice. J Med Food 20(9):821–829. https://doi.org/10.1089/jmf.2016.3859CrossRefPubMed

13.

Samsami-kor M, Daryani NE, Asl PR, Hekmatdoost A (2015) Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch Med Res 46(4):280–285. https://doi.org/10.1016/j.arcmed.2015.05.005CrossRefPubMed

14.

Sadeghi N, Mansoori A, Shayesteh A, Hashemi SJ (2020) The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis. Phytother Res 34(5):1123–1133. https://doi.org/10.1002/ptr.6581CrossRefPubMed

15.

Gutierrez-Mariscal FM, Yubero-Serrano EM, Villalba JM, Lopez-Miranda J (2019) Coenzyme Q10: from bench to clinic in aging diseases, a translational review. Crit Rev Food Sci Nutr 59(14):2240–2257. https://doi.org/10.1080/10408398.2018.1442316CrossRefPubMed

16.

Morris G, Anderson G, Berk M, Maes M (2013) Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Mol Neurobiol 48(3):883–903. https://doi.org/10.1007/s12035-013-8477-8CrossRefPubMed

17.

Yang H-L, Lin M-W, Korivi M, Wu J-J, Liao C-H, Chang C-T, Liao J-W, Hseu Y-C (2016) Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: evidence from in vitro and in vivo studies. Biochim Biophys Acta 1859(2):246–261. https://doi.org/10.1016/j.bbagrm.2015.11.001CrossRefPubMed

18.

Akbari A, Mobini GR, Agah S, Morvaridzadeh M, Omidi A, Potter E, Fazelian S, Ardehali SH, Daneshzad E, Dehghani S (2020) Coenzyme Q10 supplementation and oxidative stress parameters: a systematic review and meta-analysis of clinical trials. Eur J Clin Pharmacol 76(11):1483–1499. https://doi.org/10.1007/s00228-020-02919-8CrossRefPubMed

19.

Khodir AE, Atef H, Said E, ElKashef HA, Salem HA (2017) Implication of Nrf2/HO-1 pathway in the coloprotective effect of coenzyme Q10 against experimentally induced ulcerative colitis. Inflammopharmacology 25(1):119–135. https://doi.org/10.1007/s10787-016-0305-0CrossRefPubMed

20.

Mollazadeh H, Cicero AF, Blesso CN, Pirro M, Majeed M, Sahebkar A (2019) Immune modulation by curcumin: the role of interleukin-10. Crit Rev Food Sci Nutr 59(1):89–101. https://doi.org/10.1080/10408398.2017.1358139CrossRefPubMed

21.

Neumann C, Scheffold A, Rutz S (2019) Functions and regulation of T cell-derived interleukin-10. Semin Immunol 44:101344CrossRef

22.

Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y (2003) Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52(1):65–70. https://doi.org/10.1136/gut.52.1.65CrossRefPubMedPubMedCentral

23.

Cătană C-S, Neagoe IB, Cozma V, Magdaş C, Tăbăran F, Dumitraşcu DL (2015) Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J Gastroenterol 21(19):5823–5830. https://doi.org/10.3748/wjg.v21.i19.5823CrossRefPubMedPubMedCentral

24.

Chen W-X, Ren L-H, Shi R-H (2014) Implication of miRNAs for inflammatory bowel disease treatment: systematic review. World J Gastrointest Pathophysiol 5(2):63–70. https://doi.org/10.4291/wjgp.v5.i2.63CrossRefPubMedPubMedCentral

25.

Xu X-M, Zhang H-J (2016) miRNAs as new molecular insights into inflammatory bowel disease: crucial regulators in autoimmunity and inflammation. World J Gastroenterol 22(7):2206–2218. https://doi.org/10.3748/wjg.v22.i7.2206CrossRefPubMedPubMedCentral

26.

Schmelzer C, Kitano M, Rimbach G, Niklowitz P, Menke T, Hosoe K, Döring F (2009) Effects of ubiquinol-10 on microRNA-146a expression in vitro and in vivo. Mediat Inflamm 2009:415437. https://doi.org/10.1155/2009/415437CrossRef

27.

Ho S, Pothoulakis C, Wai Koon H (2013) Antimicrobial peptides and colitis. Curr Pharm Des 19(1):40–47. https://doi.org/10.2174/13816128130108CrossRefPubMedPubMedCentral

28.

Otte J-M, Vordenbäumen S (2011) Role of antimicrobial peptides in inflammatory bowel disease. Polymers 3(4):2010–2017. https://doi.org/10.3390/polym3042010CrossRef

29.

Koeninger L, Armbruster NS, Brinch KS, Kjaerulf S, Andersen B, Langnau C, Autenrieth SE, Schneidawind D, Stange EF, Malek NP (2020) Human β-defensin 2 mediated immune modulation as treatment for experimental colitis. Front Immunol 11:93. https://doi.org/10.3389/fimmu.2020.00093CrossRefPubMedPubMedCentral

30.

Tran DH-N, Wang J, Ha C, Ho W, Mattai SA, Oikonomopoulos A, Weiss G, Lacey P, Cheng M, Shieh C (2017) Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn’s disease, and clinical prognosis in inflammatory bowel disease. BMC Gastroenterol 17(63):2–13

31.

Ewees MG, Messiha BAS, Abo-Saif AA, El HAE-TA (2016) Is coenzyme Q10 effective in protection against ulcerative colitis? An experimental study in rats. Biol Pharm Bull 39(7):1159–1166. https://doi.org/10.1248/bpb.b16-00124CrossRefPubMed

32.

El Morsy EM, Kamel R, Ahmed MA (2015) Attenuating effects of coenzyme Q10 and amlodipine in ulcerative colitis model in rats. Immunopharmacol Immunotoxicol 37(3):244–251. https://doi.org/10.3109/08923973.2015.1021357CrossRefPubMed

33.

El-Abhar HS (2010) Coenzyme Q10: a novel gastroprotective effect via modulation of vascular permeability, prostaglandin E2, nitric oxide and redox status in indomethacin-induced gastric ulcer model. Eur J Pharmacol 649(1–3):314–319. https://doi.org/10.1016/j.ejphar.2010.09.012CrossRefPubMed

34.

Suzuki S, Gotoda T, Kusano C, Ikehara H, Miyakoshi Y, Fujii K (2019) Effect of ubiquinol intake on defecation frequency and stool form: a prospective, double-blinded, randomized control study. J Med Food 22(1):81–86. https://doi.org/10.1089/jmf.2018.4233CrossRefPubMed

35.

Brauner H, Lüthje P, Grünler J, Ekberg N, Dallner G, Brismar K, Brauner A (2014) Markers of innate immune activity in patients with type 1 and type 2 diabetes mellitus and the effect of the anti-oxidant coenzyme Q 10 on inflammatory activity. Clin Exp Immunol 177(2):478–482. https://doi.org/10.1111/cei.12316CrossRefPubMedPubMedCentral

36.

http://www.bt-laboratory.com/product/human-interleukin-17-elisa-kit-2/. Accessed 12 Nov 2019

37.

http://www.bt-laboratory.com/product/human-nuclear-factor-erythroid-2-related-factor-2-elisa-kit/. Accessed 12 Nov 2019

38.

http://www.bt-laboratory.com/product/human-cathelicidin-antimicrobial-peptide-elisa-kit-2/. Accessed 12 Nov 2019

39.

https://www.diaclone.com/p-768. Accessed 12 Mar 2019

40.

https://www.fishersci.se/shop/products/nfkb-p65-total-instantone-elisakit/15580787?searchHijack=true&searchTerm=15580787&searchType=RAPID&matchedCatNo=15580787/. Accessed 15 Feb 2020

41.

Farsi F, Heshmati J, Keshtkar A, Irandoost P, Alamdari NM, Akbari A, Janani L, Morshedzadeh N, Vafa M (2019) Can coenzyme Q10 supplementation effectively reduce human tumor necrosis factor-alpha and interleukin-6 levels in chronic inflammatory diseases? A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 148:104290. https://doi.org/10.1016/j.phrs.2019.104290CrossRefPubMed

42.

Sepidarkish M, Akbari-Fakhrabadi M, Daneshzad E, Yavari M, Rezaeinejad M, Morvaridzadeh M, Heshmati J (2020) Effect of omega-3 fatty acid plus vitamin E Co-supplementation on oxidative stress parameters: a systematic review and meta-analysis. Clin Nutr 39(4):1019–1025. https://doi.org/10.1016/j.clnu.2019.05.004CrossRefPubMed

43.

Li L, Xu D, Lin J, Zhang D, Wang G, Sui L, Ding H, Du J (2017) Coenzyme Q10 attenuated β-amyloid25–35–induced inflammatory responses in PC12 cells through regulation of the NF–κB signaling pathway. Brain Res Bull 131:192–198. https://doi.org/10.1016/j.brainresbull.2017.04.014CrossRefPubMed

44.

Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F (2008) Functions of coenzyme Q10 in inflammation and gene expression. BioFactors 32(1–4):179–183. https://doi.org/10.1002/biof.5520320121CrossRefPubMed

45.

Fouad AA, Al-Mulhim AS, Jresat I (2013) Therapeutic effect of coenzyme Q10 against experimentally-induced hepatocellular carcinoma in rats. Environ Toxicol Pharmacol 35(1):100–108. https://doi.org/10.1016/j.etap.2012.11.016CrossRefPubMed

46.

Nyariki JN, Ochola LA, Jillani NE, Nyamweya NO, Amwayi PE, Yole DS, Azonvide L, Isaac AO (2019) Oral administration of coenzyme Q10 protects mice against oxidative stress and neuro-inflammation during experimental cerebral malaria. Parasitol Int 71:106–120. https://doi.org/10.1016/j.parint.2019.04.010CrossRefPubMed

47.

Boroujeni MB, Khayat ZK, Anbari K, Niapour A, Gholami M, Am G (2017) Coenzyme Q10 protects skeletal muscle from ischemia-reperfusion through the NF-kappa B pathway. Perfusion 32(5):372–377. https://doi.org/10.1177/0267659116683790CrossRefPubMed

48.

Schmelzer C, Niklowitz P, Okun JG, Haas D, Menke T, Döring F (2011) Ubiquinol-induced gene expression signatures are translated into altered parameters of erythropoiesis and reduced low density lipoprotein cholesterol levels in humans. IUBMB Life 63(1):42–48. https://doi.org/10.1002/iub.413CrossRefPubMed

49.

Tsai K-L, Huang Y-H, Kao C-L, Yang D-M, Lee H-C, Chou H-Y, Chen Y-C, Chiou G-Y, Chen L-H, Yang Y-P (2012) A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways. J Nutr Biochem 23(5):458–468. https://doi.org/10.1016/j.jnutbio.2011.01.011CrossRefPubMed

50.

Espinosa-Diez C, Miguel V, Mennerich D, Kietzmann T, Sánchez-Pérez P, Cadenas S, Lamas S (2015) Antioxidant responses and cellular adjustments to oxidative stress. Redox Biol 6:183–197. https://doi.org/10.1016/j.redox.2015.07.008CrossRefPubMedPubMedCentral

51.

Ahmed SMU, Luo L, Namani A, Wang XJ (1863) Tang X (2017) Nrf2 signaling pathway: pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis 2:585–597. https://doi.org/10.1016/j.bbadis.2016.11.005CrossRef

52.

Choi H-K, Pokharel YR, Lim SC, Han H-K, Ryu CS, Kim SK, Kwak MK, Kang KW (2009) Inhibition of liver fibrosis by solubilized coenzyme Q10: role of Nrf2 activation in inhibiting transforming growth factor-β1 expression. Toxicol Appl Pharmacol 240(3):377–384. https://doi.org/10.1016/j.taap.2009.07.030CrossRefPubMed

53.

Pala R, Orhan C, Tuzcu M, Sahin N, Ali S, Cinar V, Atalay M, Sahin K (2016) Coenzyme Q10 supplementation modulates NFκB and Nrf2 pathways in exercise training. J Sports Sci Med 15(1):196–203PubMedPubMedCentral

54.

AlOmar SY, Fahad AA, Moneim AEA, Metwally DM, Elkhadragy MF, Kassab RB (2019) The neuroprotective role of coenzyme Q10 against lead acetateinduced neurotoxicity is mediated by antioxidant, anti-inflammatory and anti-apoptotic activities. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph16162895CrossRef

55.

Sangsefidi ZS, Yaghoubi F, Hajiahmadi S, Hosseinzadeh M (2020) The effect of coenzyme Q10 supplementation on oxidative stress: a systematic review and meta-analysis of randomized controlled clinical trials. Food Sci Nutr 8(4):1766–1776. https://doi.org/10.1002/fsn3.1492CrossRefPubMedPubMedCentral

56.

Olivieri F, Lazzarini R, Babini L, Prattichizzo F, Rippo MR, Tiano L, Di Nuzzo S, Graciotti L, Festa R, Brugè F (2013) Anti-inflammatory effect of ubiquinol-10 on young and senescent endothelial cells via miR-146a modulation. Free Radic Biol Med 63:410–420. https://doi.org/10.1016/j.freeradbiomed.2013.05.033CrossRefPubMed

57.

Wu H, Fan H, Shou Z, Xu M, Chen Q, Ai C, Dong Y, Liu Y, Nan Z, Wang Y (2019) Extracellular vesicles containing miR-146a attenuate experimental colitis by targeting TRAF6 and IRAK1. Int Immunopharmacol 68:204–212. https://doi.org/10.1016/j.intimp.2018.12.043CrossRefPubMed

58.

Pekow JR, Kwon JH (2012) MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis 18(1):187–193. https://doi.org/10.1002/ibd.21691CrossRefPubMed

59.

Arenas-Jal M, Suñé-Negre J, García-Montoya E (2020) Coenzyme Q10 supplementation: efficacy, safety, and formulation challenges. Compr Rev Food Sci Food Saf 19(2):574–594. https://doi.org/10.1111/1541-4337.12539CrossRefPubMed

60.

Mantle D, Dybring A (2020) Bioavailability of coenzyme Q10: an overview of the absorption process and subsequent metabolism. Antioxidants (Basel) 9(5):386. https://doi.org/10.3390/antiox9050386CrossRef

61.

Vitetta L, Leong A, Zhou J, Dal Forno S, Hall S, Rutolo D (2018) The plasma bioavailability of coenzyme Q10 absorbed from the gut and the oral mucosa. J Funct Biomater 9(4):73. https://doi.org/10.3390/jfb9040073CrossRefPubMedCentral

Titel: RETRACTED ARTICLE: A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis
Publikationsdatum: 23.02.2021
Erschienen in: European Journal of Nutrition / Ausgabe 6/2021
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-021-02514-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

RETRACTED ARTICLE: A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis

Abstract

Purpose

Methods

Results

Conclusions

Trial Registration

Graphic abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Trial Registration

Graphic abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Effects of gastrointestinal delivery of non-caloric tastants on energy intake: a systematic review and meta-analysis

Eating-out behaviors, associated factors and associations with obesity in Chinese school children: findings from the childhood obesity study in China mega-cities

Associations between maternal vitamin D status during three trimesters and cord blood 25(OH)D concentrations in newborns: a prospective Shanghai birth cohort study

Association of iron supplementation and deworming with early childhood development: analysis of Demographic and Health Surveys in ten low- and middle-income countries

Red meat consumption and biological markers of metabolic disorders

Diabetes-induced cardiomyopathy is ameliorated by heat-killed Lactobacillus reuteri GMNL-263 in diabetic rats via the repression of the toll-like receptor 4 pathway

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin